Shares of ContraFect Corp (NASDAQ:CFRX) shot up 12.4% during mid-day trading on Thursday . The stock traded as high as $2.31 and last traded at $2.17. 580,525 shares were traded during mid-day trading, an increase of 176% from the average session volume of 210,709 shares. The stock had previously closed at $1.93.
Several hedge funds and other institutional investors have recently made changes to their positions in CFRX. Birchview Capital LP raised its stake in shares of ContraFect by 56.5% in the third quarter. Birchview Capital LP now owns 1,135,082 shares of the biotechnology company’s stock valued at $1,260,000 after acquiring an additional 410,000 shares in the last quarter. Fosun International Ltd acquired a new stake in shares of ContraFect in the third quarter valued at $9,435,000. 683 Capital Management LLC acquired a new stake in shares of ContraFect in the third quarter valued at $2,886,000. Renaissance Technologies LLC raised its stake in shares of ContraFect by 156.6% in the fourth quarter. Renaissance Technologies LLC now owns 194,500 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 118,700 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in shares of ContraFect by 167.2% in the fourth quarter. Deutsche Bank AG now owns 116,224 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 72,732 shares in the last quarter. Institutional investors and hedge funds own 61.74% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “ContraFect (CFRX) Shares Up 12.4%” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://weekherald.com/2018/03/08/contrafect-cfrx-shares-up-12-4.html.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.